Home Providence Medical Technology Inc.

Providence Medical Technology Inc.

Providence Medical Technology Secures $25 Million In Equity Financing

9/20/18: The proceeds of the financing will be used to accelerate commercial expansion and clinical development of its DTRAX® line of cervical fusion instruments designed to help patients suffering from advanced cervical spine conditions.

Providence Medical Technology Announces FDA 510(k) Clearance for DTRAX® Spinal System

5/22/18: "With the FDA 510(k) clearance of DTRAX Spinal System, Providence now has the only sterile-packaged, single-use set of instruments specifically cleared for posterior cervical fusion," said Providence CEO Jeff Smith. "Our unique, single-use instruments assist surgeons in performing the steps of a traditional posterior cervical fusion. We believe DTRAX represents a landmark innovation for cervical fusion benefiting patients, surgeons, facilities, and payers."

Providence Medical Technology Expands Offering of Posterior Cervical Fusion Solutions

9/27/17: DTRAX Spinal System is a set of sterile packaged, single-use instruments designed to perform posterior cervical fusion and has been used in over 7,000 cases worldwide. Posterior cervical fusion is indicated for patients with symptomatic nerve root involvement and/or mechanical instability.

Providence Medical Technology Announces Publication of Two New Studies Supporting Tissue-Sparing Posterior Cervical Fusion

7/10/17: In the first study published by Lenzi J, et al. in World Neurosurgery (2017), the authors report results from the first ever prospective, randomized, controlled trial comparing operative results using the DTRAX® Expandable Cage system versus conservative care for patients diagnosed with single-level cervical radiculopathy.

Providence Medical Technology Announces Issuance of Four Additional U.S. Patents

4/27/18: "We have invested tremendous resources over the years in filing both broad and detailed disclosures covering the important aspects of our technology for tissue-sparing posterior cervical and spinal intervention," commented Jeff Smith, Chief Executive Officer. "We are extremely pleased with the continued and accelerating growth of our patent portfolio as it provides the means to protect our innovations and rapidly expanding business.

Must Read

New Study Validates Rigorous Safety Measures Needed To Reduce Mercury Exposure During Dental Amalgam Filling Removal

"For decades, our non-profit organization has been concerned about this issue and collected research about amalgam fillings, all of which contain approximately 50% mercury, a known neurotoxin," explains IAOMT President Michael Rehme, DDS, NMD.  "Based on this science, we have strongly recommended that safety measures be enacted for dental procedures involving these silver-colored fillings, and we have also intensely advocated for the end of dental amalgam usage."